Search results
Results from the WOW.Com Content Network
The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies.An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus.
The substems according to the nomenclature of monoclonal antibodies are shown below each antibody. Date: 14 February 2010, 13:34 (UTC) Source: Antibody_je2.neutral.svg; General policies for monoclonal antibodies (PDF). World Health Organization (2009-12-18). Author
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies. The abbreviations in the column Type are as follows:
Download as PDF; Printable version; In other projects ... Antibody-drug conjugates ... out of approximately 307 total.
Download as PDF; Printable version; In other projects ... This category has the following 6 subcategories, out of 6 total. A. ... Antibody-drug conjugates (57 P ...
[[Category:Monoclonal antibody templates]] to the <includeonly> section at the bottom of that page. Otherwise, add <noinclude>[[Category:Monoclonal antibody templates]]</noinclude> to the end of the template code, making sure it starts on the same line as the code's last character.
Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs.In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. [1]
This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. . Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary ...